Clinical value of a whole blood interferon‑γ release assay for the diagnosis of Mycobacterium tuberculosis infection during antitubercular treatment
- Authors:
- Haifeng Wang
- Zhenyun Li
- Qunmei Zhang
- Guangjian Lu
- Qingjiang Wang
- Ligong Zhang
- Chenguang Zhang
View Affiliations
Affiliations: The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan 453100, P.R. China, Department of Laboratory Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
- Published online on: May 21, 2013 https://doi.org/10.3892/etm.2013.1127
-
Pages:
455-458
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of this study was to evaluate the sensitivity and specificity of a whole blood interferon‑γ release assay, the QuantiFERON®‑TB Gold In‑Tube (QFT‑GIT) test, in the diagnosis of Mycobacterium tuberculosis (MTB) infection, and to assess its monitoring role during antitubercular treatment. In total, 20 patients received the QFT test, along with other commonly‑used tests, prior to, and following, 2‑ and 6‑month courses of antitubercular treatment; the results were compared and statistically analyzed. The rate of positive results for tuberculosis (TB) was 95% for the QFT test, which was significantly higher compared with those for the purified protein derivative (PPD; 55%) and the antitubercular antibody tests (15%), as well as the acid‑fast bacilli smear (20%) and cultures for TB (20%; P<0.05 for all). The sensitivity and specificity of the QFT test were 96 and 93.8%, respectively. The positive result rate obtained with the QFT test was significantly higher in the TB group compared with that in the non‑TB group (6.3%; P<0.05). Moreover, the positive result rate obtained with the QFT test was significantly lower in the 6‑month‑treated group compared with that in the 2‑month group (P<0.05). In conclusion, the QFT test is a sensitive and specific method for rapidly diagnosing MTB infection, and has an improved practical clinical value in evaluating antitubercular therapies compared with that of the PPD test.
View References
|
1.
|
Castillo EF, Dekonenko A, Arko-Mensah J,
et al: Autophagy protects against active tuberculosis by
suppressing bacterial burden and inflammation. Proc Natl Acad Sci
USA. 109:E3168–E3176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Zhang Y, Sun YM, Xu XH and Lv LX:
Diagnostic value of interferon-gamma release assay T-SPOT.TB for
tuberculosis Chinese. Journal of Clinicians. 4:2431–2434. 2010.
|
|
3.
|
Dinnes J, Deeks J, Kunst H, et al: A
systematic review of rapid diagnostic tests for the detection of
tuberculosis infection. Health Technol Assess. 11:1–196. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Jung YJ, Lyu J, Yoo B, et al: Combined use
of a TST and the T-SPOT®.TB assay for latent
tuberculosis infection diagnosis before anti-TNF-α treatment. Int J
Tuberc Lung Dis. 16:1300–1306. 2012.PubMed/NCBI
|
|
5.
|
Ramos JM, Robledano C, Masiá M, Belda S,
Padilla S, Rodríguez JC and Gutierrez F: Contribution of interferon
gamma release assays testing to the diagnosis of latent
tuberculosis infection in HIV-infected patients: a comparison of
QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test.
BMC Infect Dis. 12:1692012. View Article : Google Scholar
|
|
6.
|
Shah M, Miele K, Choi H, DiPietro D,
Martins-Evora M, Marsiglia V and Dorman S: QuantiFERON-TB gold
in-tube implementation for latent tuberculosis diagnosis in a
public health clinic: a cost-effectiveness analysis. BMC Infect
Dis. 12:3602012. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Al-Zamel FA: Detection and diagnosis of
Mycobacterium tuberculosis. Expert Rev Anti Infect Ther.
7:1099–1108. 2009. View Article : Google Scholar
|
|
8.
|
Lalvani A and Pareek M: Interferon gamma
release assays: principles and practice. Enferm Infecc Microbiol
Clin. 28:245–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Diel R, Loddenkemper R and Nienhaus A:
Evidence-based comparison of commercial interferon-gamma release
assays for detecting active TB: a metaanalysis. Chest. 137:952–968.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wu D, Huang S and Guo A: Clinical
significance of the γ-interferon release test for the diagnosis of
Mycobacterium tuberculosis infection. Guangdong Yi Xue.
32:1317–1319. 2011.(In Chinese).
|
|
11.
|
Cheng X and Jiang J: Value of
immunodiagnostic techniques on diagnosis of pulmonary and
extrapulmonary tuberculosis. International Journal of Respiration.
31:464–467. 2011.
|
|
12.
|
Zhang S, Shao L, Mo L, et al: Evaluation
of gamma interferon release assays using Mycobacterium
tuberculosis antigens for diagnosis of latent and active
tuberculosis in Mycobacterium bovis BCG-vaccinated
populations. Clin Vaccine Immunol. 17:1985–1990. 2010.
|
|
13.
|
Lian G and Wang Y: Clinical application of
interferon gamma release assays for diagnosis of latent
tuberculosis infection in children. Journal of Clinical Pediatrics.
28:116–119. 2010.
|
|
14.
|
Zhang H, Huang S and Luo Z: IFN-γ release
assays for rapid diagnosis of active tuberculosis: clinical
application. Chinese Journal of Nosocomiology. 19:1898–1899.
2009.
|
|
15.
|
Zhang M, Wang H, Liao M, et al: Diagnosis
of latent tuberculosis infection in bacille Calmette-Guérin
vaccinated subjects in China by interferon-gamma ELISpot assay. Int
J Tuberc Lung Dis. 14:1556–1563. 2010.
|
